The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Αβ deposits is beneficial such as Alzheimers disease.Linvention concerne de nouveaux inhibiteurs de lenzyme BACE1. Différents aspects de linvention concernent des compositions pharmaceutiques contenant lesdits composés, ainsi que les utilisations de ces composés dans le traitement de troubles dans lesquels la réduction de dépôts de bêta-amyloïdes est bénéfique, tels que la maladie dAlzheimer.